Cargando…

Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells

Previously, we have shown that epidermal growth factor receptor (EGFR)-selective delivery of soluble tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL), by genetic fusion to antibody fragment scFv425, enhances the tumor-selective pro-apoptotic activity of sTRAIL. Insight into the respe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bremer, Edwin, de Bruyn, Marco, Samplonius, Douwe F., Bijma, Theo, ten Cate, Bram, de Leij, Lou F. M. H., Helfrich, Wijnand
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2008
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2491411/ https://www.ncbi.nlm.nih.gov/pubmed/18504532 http://dx.doi.org/10.1007/s00109-008-0348-9

Ejemplares similares

Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction
por: Hendriks, Djoke, et al.
Publicado: (2016)

The Glycan-Binding Protein Galectin-9 Has Direct Apoptotic Activity toward Melanoma Cells
por: Wiersma, Valerie R, et al.
Publicado: (2012)

A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members
por: He, Yuan, et al.
Publicado: (2017)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
por: Koopmans, Iris, et al.
Publicado: (2018)

Assessment of concentrations of sTRAIL ligand and its receptors sTRAIL-R1 and sTRAIL-R2 – markers monitoring the course of the extrinsic pathway of apoptosis induction: potential application in ovarian cancer diagnostics
por: Mielczarek-Palacz, Aleksandra, et al.
Publicado: (2015)

sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment
por: Huang, Ying, et al.
Publicado: (2017)

Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα “don’t eat me” immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation
por: Hendriks, Mark A. J. M., et al.
Publicado: (2020)

Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo
por: de Bruyn, Marco, et al.
Publicado: (2010)

Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer
por: Bisgin, Atil, et al.
Publicado: (2012)

Association of circulating sTRAIL and high-sensitivity CRP with type 2 diabetic nephropathy and foot ulcers
por: Arık, Hasan Onur, et al.
Publicado: (2013)

Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR
por: Ploeg, Emily Maria, et al.
Publicado: (2023)

The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux
por: Wiersma, Valerie R, et al.
Publicado: (2015)

The Ever-Expanding Immunomodulatory Role of Calreticulin in Cancer Immunity
por: de Bruyn, Marco, et al.
Publicado: (2015)

Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model
por: Crommentuijn, Matheus HW, et al.
Publicado: (2016)

Engineered sTRAIL-armed MSCs overcome STING deficiency to enhance the therapeutic efficacy of radiotherapy for immune checkpoint blockade
por: Huang, Kevin Chih-Yang, et al.
Publicado: (2022)

Galectin-9 Activates and Expands Human T-Helper 1 Cells
por: Gooden, Marloes J. M., et al.
Publicado: (2013)

Carbon monoxide-Releasing Molecule-2 (CORM-2) attenuates acute hepatic ischemia reperfusion injury in rats
por: Wei, Yunwei, et al.
Publicado: (2010)

Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects
por: Yu, R, et al.
Publicado: (2013)

Anti-Cancer Effect of Neural Stem Cells Transfected with Carboxylesterase and sTRAIL Genes in Animals with Brain Lesions of Lung Cancer
por: Kim, Jung Hak, et al.
Publicado: (2023)

Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRPα axis
por: Hendriks, Mark A.J.M., et al.
Publicado: (2021)

Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selective eliminate carcinoma cells
por: Britsch, Isabel, et al.
Publicado: (2023)

CD20-selective inhibition of CD47-SIRPα “don't eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab
por: van Bommel, Peter E., et al.
Publicado: (2017)

The inhibitory effect of human umbilical cord mesenchymal stem cells expressing anti-HAAH scFv-sTRAIL fusion protein on glioma
por: Xue, Tian, et al.
Publicado: (2022)

A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer
por: Ploeg, Emily Maria, et al.
Publicado: (2023)

Health outcomes, education, healthcare delivery and quality – 3038: The relation of sTRAIL levels and quality of life in omalizumab using severe persistent allergic asthma patients
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Basic and clinical immunology – 3031. The correlation between serum protemics patterns of sTRAIL and CXCL8 with FDG-PET/CT findings in bevacizumab treated colon cancers
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Immunotherapy – 2071. Strail levels decreased after allergen-subcutaneous specific immunotherapy
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL
por: Jordaan, Sandra, et al.
Publicado: (2017)

Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects
por: Eggleton, Paul, et al.
Publicado: (2011)

CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy
por: Komdeur, Fenne L., et al.
Publicado: (2016)

Endogenous TRAIL-R4 critically impacts apoptotic and non-apoptotic TRAIL-induced signaling in cancer cells
por: Rambow, Anna-Christina, et al.
Publicado: (2022)

A proof-of-concept study on the use of a fluorescein-based (18)F-tracer for pretargeted PET
por: Helbert, Hugo, et al.
Publicado: (2022)

Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death
por: Brunekreeft, Kim L, et al.
Publicado: (2014)

Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cells
por: Willms, Anna, et al.
Publicado: (2019)

TRAIL-β and TRAIL-γ: two novel splice variants of the human TNF-related apoptosis-inducing ligand (TRAIL) without apoptotic potential
por: Krieg, A, et al.
Publicado: (2003)

Changes in the Concentration of Markers Participating in the Regulation of the Apoptosis Receptor Pathway Involving Soluble Tumour Necrosis Factor Ligand Inducing Apoptosis (sTRAIL) and Osteoprotegerin (OPG) in the Serum of Women with Ovarian Cancer—Participation in Pathogenesis or a Possible Clinical Use?
por: Mielczarek-Palacz, Aleksandra, et al.
Publicado: (2020)

TRAIL is involved in CpG ODN-mediated anti-apoptotic signals
por: LIM, EUN-JUNG, et al.
Publicado: (2011)

A quantitative reverse transcriptase polymerase chain reaction-based assay to detect carcinoma cells in peripheral blood.
por: Helfrich, W., et al.
Publicado: (1997)

Impact of Extracellular pH on Apoptotic and Non-Apoptotic TRAIL-Induced Signaling in Pancreatic Ductal Adenocarcinoma Cells
por: Hagelund, Sofie, et al.
Publicado: (2022)

Malaria sporozoite proteome leaves a trail
por: Vignali, Marissa, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_c0fnt8g0n4beg5633g5u8vjb8u